ASHBURN, Va., Dec. 12 /PRNewswire/ -- Innocoll, Inc. announced its sales and marketing subsidiary, Innocoll Pharmaceuticals Ltd., has recently signed distribution agreements for its CollaRx GENTAMICIN SURGICAL IMPLANT in five additional territories; Turkey, Greece, Romania, Bulgaria, and Nigeria.
The product is indicated for the treatment and prevention of post-operative acquired infection and was acquired by Innocoll from Schering Plough in July of this year. Innocoll has since assumed all sales, marketing and distribution activities for the product.
Dr. Michael Myers, President and CEO of Innocoll, Inc. commented, “Since the product acquisition earlier this year, we have successfully established our sales and marketing infrastructure in key European countries. To complement our own sales effort, we have also entered into twelve distribution arrangements covering a further sixteen countries.”
Denise Carter, President of Innocoll Pharmaceuticals stated, “I am pleased with our continued progress in expanding the market presence of CollaRx GENTAMICIN SURGICAL IMPLANT. We are already seeing significant results from our sales force and these new distribution arrangements will serve to further expand the product’s reach. It is our intention to continue to focus on the product’s growth opportunities in new territories as well as exploring new indications.”
The product was developed using Innocoll’s proprietary collagen-based technology, CollaRx(TM), and has been approved in 49 countries. It is marketed under the following different trade names (COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R) IMPLANT, GARAMYCIN(R) SCHWAMM, DURACOL(R), DURACOLL(R), GENTACOL(R), GENTACOLL(R), GARACOL(R), GARACOLL(R), CRONOCOL(R)) in Europe, Central and South America, Africa and Asia.
About GENTAMICIN SURGICAL IMPLANT
GENTAMICIN SURGICAL IMPLANT is a biodegradable leave-behind implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin, and is indicated as an adjunct to systemic antibiotic therapy for the treatment and prevention of post-surgical acquired infection in both hard and soft tissues. It is based on Innocoll’s CollaRx(TM) technology, a proprietary collagen-based system which locally delivers a wide variety of drug products, and can be formulated for implantable or topical application as a lyophilized sponge or as a cast film.
About Innocoll, Inc.
Innocoll is a privately held, international specialty pharmaceutical company engaged in the development and commercialization of advanced, differentiated medical products using its proprietary collagen-based technologies, CollaRx(TM) and LiquiColl(R). For more information, please visit www.innocoll.com. For product or pipeline information, please visit www.innocoll-pharma.com.
Innocoll, Inc.
CONTACT: Denise Carter, President of Innocoll Pharmaceuticals,+1-215-765-0149
